Over 50% of ST-segment elevation myocardial infarction (STEMI) patients suffer multi-vessel coronary artery disease, which is known to be associated with worse prognosis. Treatment strategies used in clinical practice vary from acute multi-vessel percutaneous coronary intervention (PCI), through staged PCI procedures to a conservative approach with primary PCI of only the infarct-related artery (IRA) and subsequent medical therapy unless recurrent ischaemia occurs. Each approach has advantages and disadvantages. This review paper summarizes the international experience and authors' opinion on this clinically important question. Multi-vessel disease in STEMI is not a single entity and thus the treatment approach should be individualized. However, the following general rules can be proposed till future large randomized trials prove otherwise:
Introduction
Primary percutaneous coronary intervention (p-PCI) has become the treatment of choice for patients presenting with ST-segment elevation myocardial infarction (STEMI) when it can be performed expeditiously by an experienced team. 1 -6 The goal is restoration of flow within 90 min of presentation to a PCI-equipped centre or within 120 min from the time of the first medical contact. 7, 8 This strategy has been found to be superior to thrombolytic therapy in improving morbidity and mortality. An important piece of information gained at the time of angiography and p-PCI is information not only about the culprit lesion but also about the extent and severity of the underlying coronary artery disease. In patients presenting with STEMI, multi-vessel coronary artery disease is found to be present from 41 to 67% of patients depending upon the baseline characteristics (especially age) of the specific population studied; 9 -12 however, in one study only 10% of STEMI patients initially treated by p-PCI had a clinical indication for non-culprit PCI during the subsequent follow-up of up to 3 years. 13 The presence of multi-vessel disease has been found to be associated with worse prognosis in patients with STEMI. 14 Identification of optimal strategies for treating these patients is the subject of considerable interest and controversy. Treatment strategies vary widely from an aggressive approach which treats all significant lesions in the acute phase of p-PCI to a conservative approach with p-PCI of only the infarct-related artery (IRA) and subsequent medical therapy unless recurrent ischaemia occurs. Between these two extremes are other alternatives; mainly that of staged procedures with the IRA treated acutely and other lesions treated later during the hospital stay or within the first month following discharge. There is no randomized data to definitely answer the issues about the specific scientific merits of any of these approaches. However, there are increasing data from observational series. Each approach has advantages and disadvantages. This review paper summarizes the international experience and authors' opinion on this clinically important question. The authors have not tried to do a formal 'meta-analysis' and rather preferred to describe the current knowledge and to offer their view on the subject.
Aggressive approach: acute multi-vessel percutaneous coronary intervention during ST-segment elevation myocardial infarction
The potential advantages of the aggressive approach are completeness of revascularization, treatment of any secondary potentially unstable lesions, and possible shortening of cumulative hospital stay. The main disadvantages are increased contrast load (and thus increased risk of contrast-induced nephropathy), haemodynamic instability in the acute setting, and potentially disastrous complications of non-infarct artery PCI ( Table 1) . Several studies reported promising results with multi-vessel PCI strategy. One group 15 reported a decrease in recurrent infarctions or ischaemia, but no survival benefit. Rigattieri et al. 16 found that p-PCI of the culprit vessel alone with subsequent medical treatment has better early outcomes, whereas multi-vessel-staged PCI tended to better long-term outcomes. Another Italian study 17 Conservative approach: acute percutaneous coronary intervention of the infarct-related artery alone (followed by medical therapy unless recurrent ischaemia occurs)
Other studies reported better outcomes with a more conservative strategy of p-PCI only on the IRA in the acute phase ( Table 2 ). The study of Corpus et al. 21 described significantly higher risk of re-infarction (13.0 vs. 2.8%, P , .001) and even of repeat revascularization (25 vs. 15%, P ¼ 0,007) among 506 patients when treated by multi-vessel PCI (152 patients) when compared with IRA-only PCI (354 patients).
The New York State PCI Registry 22 reported that in haemodynamically stable patients with multi-vessel disease, acute phase multi-vessel PCI results in an increased in-hospital mortality (2.4%) when compared with IRA-only PCI (0.9%, P ¼ 0,04). On the contrary, patients undergoing staged multi-vessel PCI within 60 days after the index procedure had a significantly lower 12-month mortality rate than patients undergoing culprit vessel PCI only (1.3 vs. 3.3%, P ¼ 0.04). Khattab et al. 23 found no mortality benefit from acute multi-vessel PCI. Roe et al. 24 described even increased mortality with acute multivessel PCI strategy and also an increased risk of major adverse cardiac events with this strategy. The US National Cardiovascular Data Registry (28 936 STEMI patients) found increased mortality among 3087 patients with cardiogenic shock when primary multivessel PCI was used 25 and also a trend to increased mortality with this strategy among all STEMI patients ( Figure 2 Also one small single-centre retrospective study of Mohamad et al. 28 concluded that intervention of non-critical lesions did not seem to improve MACEs or all-cause mortality at 1 year of follow-up and might in fact have had a detrimental effect on outcomes.
A recently published secondary analysis of the APEX-acute myocardial infarction trial 12 found non-IRA PCI to be performed only in 9.9% of patients with STEMI and multi-vessel disease. Ninety-day death and death/congestive heart failure/shock were higher in this non-IRA group compared with the IRA-only PCI group (12.5 vs. 5.6%, P ,0.001 and 17.4 vs. 12.0%, P , 0.020, respectively). After adjusting for patient and procedural characteristics as well as propensity for performing non-IRA PCI, this procedure remained independently associated with an increased hazard of 90-day mortality [adjusted hazard ratio 2.44, 95% CI (1.55-3.83), P ,0.001].
Intermediate approach: acute percutaneous coronary intervention of the infarct-related artery followed by staged percutaneous coronary intervention of secondary lesions
The SWISSI II randomized trial 29 found elective (non-acute) PCI to be superior to medical therapy for patients with proven silent myocardial ischaemia after STEMI ( Figure 3 ; Table 3 ).
There are no published large randomized trials. We found only five small randomized studies, 17,26,30 -32 enrolling between 69 and 219 patients per study. These studies have significant limitations, the main being extremely low mortality (1.9% short-term and 3.8% long-term), which may reflect the high degree of preselection with high-risk STEMI patients being excluded. Four of these five randomized trials reported short-term mortality of STEMI patients between 0% (two studies) and 1.4%. Thus, their results may not be applicable to routine clinical practice. One small randomized study 33 compared multi-vessel PCI vs. culprit vessel only PCI in a small mixed group of patients including patients without previous acute myocardial infarction.
Advantages and disadvantages of multi-vessel percutaneous coronary intervention in ST-segment elevation myocardial infarction
The summary of all above-mentioned trials and registries is in Table 4 . The reasons supporting multi-vessel PCI in STEMI patients and arguments against this strategy were summarized by Kornowski 34 : Reasons supporting multi-vessel PCI include:
(i) Plaque instability may not be limited to the culprit lesion, 35 but may rather involve larger areas of the coronary tree (systemic endothelial dysfunction and higher platelet activity in acute coronary syndromes). (ii) Complete coronary revascularization is known to be associated with better long-term prognosis. (iii) Patient preference: patients may feel more comfortable when going home 'after complete repair'. Our experience repeatedly showed, that when we recommend medical therapy to patients with multi-vessel disease after successful p-PCI of the IRA, some patients seek second opinion in other cardiac centres and undergo a second PCI there.....
Kornowski found more reasons against acute multi-vessel PCI:
(i) The acute phase of STEMI is a highly unstable condition (haemodynamic instability, heart failure, arrhythmias, resuscitation, and patient stress among others) and is thus certainly not an ideal situation to perform PCI of a stable stenosis, which might be intervened in probably more safely at a later phase, after stabilization. (ii) The acute phase of STEMI is an extremely prothrombotic and inflammatory milieu, which contributes to the potentially higher risk of additional PCI. (iii) Some degree of diffuse coronary spasm (either due to endothelial dysfunction or due to catecholamine use) is frequently present in the acute phase of STEMI, which may lead to possible overestimation of stenosis severity in non-infarct arteries. From literature review to real life: extreme variation of different clinical and angiographic scenarios!
The main limitation of all the above-mentioned published papers is the simplification. Patients with multi-vessel disease are divided into two groups: those treated by acute or staged multi-vessel PCI and those not treated by this strategy. The every day real-life clinical practice brings much more different clinical scenarios. The decision to proceed with multi-vessel PCI is simple in the rare ( 1% of all p-PCIs) situation when two unstable (thrombus containing) IRA can be clearly demonstrated by the acute phase coronary angiography. This is the only situation, when there is almost no doubt about the PCI strategy (the only doubt is which artery should be dilated first). However, in the vast majority of p-PCIs, a single IRA can be easily recognized and treated.
There are 60 possible scenarios based on combinations of angiographic (number of diseased vessels, lesion severity, location and type, chronic total occlusions, thrombolysis in myocardial infarction flow, collaterals, wall motion in the supplied territory, etc.) and clinical (Killip class, immediate post-PCI haemodynamic situation, renal function, etc.) findings in individual patients. Clinical decision-making in this situation is thus really complex and should be always individualized. It is unlikely that any randomized clinical trial in the future can be able to fully address this complexity and thus, experienced, wise clinical judgement will probably remain the most important factor in this difficult situation.
Functional (exercise stress) testing along with the clinical picture (patients' symptoms) should be an important part of the decisionmaking algorithm. Patients who are asymptomatic and have negative functional tests and no evidence for silent ischaemia after their first STEMI should currently be treated conservatively.
The role of coronary bypass surgery (CABG) in patients with multivessel disease after STEMI was never investigated in a randomized study; however, it is a routine part of the clinical decision making. There is no uniform agreement on the CABG indications after STEMI treated by p-PCI. In most centres, once the culprit artery was treated by PCI, the other stenosed coronary arteries are either revascularized by staged PCI or are treated conservatively. However, in specific situations (e.g. triple-vessel disease with left main stenosis, anatomy not suitable for PCI, diabetes with triple-vessel disease, etc.), CABG should remain an important part of the treatment algorithm. Obviously, the indication for CABG should be supported by residual ischaemia (spontaneous or provoked) after STEMI.
What do the guidelines recommend?
The European Society of Cardiology guidelines for PCI 37 state that in multi-vessel disease, p-PCI should be directed only at the infarct-related coronary artery. Decisions about PCI of non-culprit lesions should be done later and guided by objective evidence of residual ischaemia. Only in the setting of cardiogenic shock is there a consensus for attempting multi-vessel PCI in selected patients with multiple critical lesions. A 2009 report on the appropriateness criteria for coronary revascularization written by the expert panel of the ACCF/SCAI/STS/AATS/ AHA/ASNC 38 considers revascularization of a non-IRA during index hospitalization inappropriate in STEMI patients with successful treatment of the culprit artery by p-PCI or fibrinolysis when these patients are asymptomatic, without heart failure, have no evidence of recurrent or provocable ischaemia or did not have any unstable ventricular arrhythmias during the index hospitalization and have normal EF. On the other hand, STEMI or non-STEMI myocardial infarction patients after successful PCI of culprit artery with symptoms of recurrent myocardial ischaemia and/or high-risk findings on non-invasive stress testing performed after index hospitalization are suitable candidates for revascularization of additional coronary arteries.
Currently running/future trials
Several studies are currently running trying to contribute to this question. One such study is led by D. Wood
How to treat patients with ST-elevation (http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01065103), and another by O. Hlinomaz, and L. Groch (the PRAGUE-13 study). None of these is large enough to provide a definite answer. The authors are not currently aware about a larger ongoing study on this topic.
Conclusions
Multi-vessel disease in STEMI is not a single entity and thus the treatment approach should be individualized. However, the following general rules 39 can be proposed till future large randomized trials prove otherwise:
(i) Single-vessel acute PCI should be the default strategy (to treat only the IRA during the acute phase of STEMI). (ii) Acute multi-vessel PCI can be justified only in haemodynamically unstable patients with multiple truly critical (.90%) lesions. (iii) Significant lesions of the non-culprit arteries should be treated either medically or by staged revascularization procedures-both options are currently acceptable.
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